乳腺癌
转移
癌症研究
转移性乳腺癌
三阴性乳腺癌
体内
癌症
放射治疗
细胞凋亡
原发性肿瘤
下调和上调
肿瘤科
医学
生物
内科学
生物技术
基因
生物化学
作者
Brittany A. Simone,Tu Dan,Ajay Palagani,Lianjin Jin,Sunny Y. Han,Christopher M. Wright,Jason E. Savage,Robert Scott Gitman,Meng Kieng Lim,Juan P. Palazzo,Minesh P. Mehta,Nicole L. Simone
出处
期刊:Cell Cycle
[Taylor & Francis]
日期:2016-03-30
卷期号:15 (17): 2265-2274
被引量:40
标识
DOI:10.1080/15384101.2016.1160982
摘要
Metastatic breast cancer is devastating and triple negative breast cancers (TNBC) have a higher propensity for metastasis. Improved local control upfront in this aggressive cancer could potentially decrease its propensity toward metastasis. We sought to determine if using caloric restriction (CR) as a systemic therapy, combined with radiation therapy (IR) to the primary tumor, may impact metastatic disease.An orthotopic mouse model using a highly metastatic, luciferase-tagged TNBC cell line (4T1), was used to generate palpable tumors. Mice were then treated with CR, IR, and a combination of the two. In vivo imaging was performed for metastatic evaluation. Molecular evaluation of the tumors was performed, generating a mechanistic hypothesis for CR, which was then tested with pertinent pathway inhibition in the model.CR significantly increased the time to developing metastases, decreased the overall number and volume of lung metastases, and increased survival. CR decreased proliferation, increased apoptosis and globally downregulated the IGF-1R signaling pathway. Adding an IGF-1R/INSR inhibitor to local IR in vivo accomplished a decrease in metastases similar to CR plus IR, demonstrating the importance of the IGF-1R signaling pathway, and underscoring it as a possible mechanism for CR.CR decreased metastatic burden and therefore may complement cytotoxic therapies being used in the clinical setting for metastatic disease. Downregulation of the IGF-1R pathway, is in part responsible for this response and modulating IGF-1R directly resulted in similar improved progression-free survival. The novel use of CR has the potential to enhance clinical outcomes for patients with metastatic breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI